Drug Trial Radar · NCT05084222
Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing
Last checked: Nov 20, 2026Latest source record: Sep 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Nov 11, 2021
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Orion Corporation, Orion PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study compares Buventol® Easyhaler® and Bufomix® Easyhaler® to the current standard treatment during methacholine challenge test. The trial will also provide inspiratory flow profile data for Easyhaler inhaler. This trial is designed to provide a further evidence for the use of Easyhaler in diagnostic bronchial challenge tests and on the use of Easyhaler inhaler during obstructive event.
Conditions
- Asthma
Interventions
Buventol® Easyhaler® 200 µg/inhalation dmDPIDrug
Two doses will be administered
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPIDrug
Two doses will be administered
Ventoline® Evohaler® 100 µg/inhalation pMDIDrug
Four doses will be administered via Volumatic spacer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forced expiratory volume in one second (FEV1)Time frame: 10 minutes
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Helsinki University Hospital
Helsinki, Finland
Tampere University Hospital
Tampere, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.